Pharma channel feed – Endpoints News

Pharma channel feed

New drug price controversy looms as Biogen stuns payers with Spinraza's $750K sticker — analyst

9 years ago

Biogen, Ionis win FDA OK for spinal muscular atrophy drug Spinraza

9 years ago

WSJ's editorial page puts the blame over Exondys 51 controversy on insurers, regulators and reporters

9 years ago

ChemoCentryx grabs $50M upfront, adds development partnership with Vifor

9 years ago

The Senate dissects Martin Shkreli's scheme to grab a $1B windfall

9 years ago

Is biopharma’s Midas man Vivek Ramaswamy building a new IPO vehicle with Dermavant deal?

9 years ago

Incyte antes up $200M — promises billions more — to launch a bispecific development deal with Merus

9 years ago

Bristol-Myers doubles down on PsiOxus in $936M-plus “armed” oncolytic virus deal

9 years ago

Editas fires back at CRISPR/Cas9 rivals, bagging an exclusive license to a tech upgrade

9 years ago

Celgene, Versant back a biotech merger, building an antibody pipeline and lining up for the clinic

9 years ago

CRISPR/Cas9 players create an IP alliance as the war with Editas heats up

9 years ago

In a first, AstraZeneca gains rights to an antisense KRAS drug in $165M Ionis deal

9 years ago

Gilead’s rep takes another punishing blow as a bad, no good, awful year just got worse

9 years ago

Novartis bags a new eczema drug, builds dermatology pipeline with Ziarco buyout

9 years ago

After some careful thinking, Celgene strikes a $295M discovery deal on neurodegeneration

9 years ago

FDA slaps a hold on Agios’ PK drug, forcing the biotech to kill it in favor of an internal rival

9 years ago

Pfizer racks up an FDA approval for eczema blockbuster hopeful crisaborole

9 years ago

New drug OKs fell off a cliff in 2016 and the FDA wants you to know why

9 years ago

INC Research promises 550 new jobs as it plots headquarters move

9 years ago

Analysts track a payer revolt against Sarepta’s controversial Duchenne drug

9 years ago

It’s the law: Obama signs widely popular 21st Century Cures Act

9 years ago

GSK preps for vaccine R&D expansion, 200 hires for new global hub

9 years ago

Gates-backed Exicure wraps 2016 with its first major collaboration and a plan for the year ahead

9 years ago

Moving on past sola wreckage, Lilly doubles down on one more Alzheimer’s drug from AstraZeneca

9 years ago

First page Previous page 335 336 337338339 340 341 Next page Last page